Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27908 | 0.84 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL15602898 | 0.84 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL29952148 | 0.77 | ENPP2 (0.53) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL29209517 | 0.77 | ENPP2 (0.52) | ENPP2TTR | |
| SCHEMBL633226 | 0.77 | TSHR (0.50) | TTRALBMEN1KMT2AGRM5 | |
| SCHEMBL5852713 | 0.77 | VCAM1 (0.43) | TTRALBMEN1KMT2AGRM5 | |
| SCHEMBL177673 | 0.77 | ENPP2 (0.52) | ENPP2TTR | |
| SCHEMBL874242 | 0.75 | ENPP2 (0.52) | ENPP2GRM5 | |
| SCHEMBL16398417 | 0.75 | ENPP2 (0.52) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL3326314 | 0.75 | ENPP2 (0.52) | ENPP2TTRALBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4619386-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119798179-A | Novel compound and organic light emitting device using the same | 株式会社LG化学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024259171-A9 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024104932-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024084217-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-04-25 | — | — | WO | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013054108-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-18 | — | — | WO | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | ENPP2 1176/4885TTR 1698/4885ALB 2519/4885 |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ENPP2 642/4885TTR 1344/4885ALB 4757/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | ENPP2 3395/4885TTR 4256/4885ALB 4767/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ENPP2 930/4885TTR 3110/4885ALB 3556/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | ENPP2 519/4885TTR 1160/4885ALB 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.